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Background: Depression is very prevalent in COPD and may be associated with poor clinical
outcomes.
Method: This was a multicenter, cross-sectional study aimed at evaluating the prevalence of
depression and moderate to severe depression in COPD. Depressive symptoms were evaluated
with the Beck’s Depression Inventory. The COPD assessment test (CAT) and the EuroQoL-5 di-
mensions (EQ-5D) questionnaires were used to evaluate health-related quality of life (HRQoL).
Severity of COPD was assessed with the BODEx index and physical activity was estimated by the
mean self-declared time walked per day.
Results: A total of 836 patients were included and up to 74.6% had some degree of depression
with 51.5% having moderate to severe depression. On multivariate analysis, moderate to se-
vere depression was associated with suicidal ideation (OR, 6.12; 95% confidence interval
(CI), 1.36e28.24), worse quality of life: EQ-5D (OR, 0.89; 95%CI, 0.86e0.93) and worse CAT
scores (OR, 1.32; 95%CI, 1.19e1.46). When questionnaires were not included in the analysis,
significant depression was associated with the Charlson comorbidity index, minutes walked
per day and BODEx score.Department, Hospital Universitari Vall d’Hebron, P. Vall d’Hebron 119-129, ESe08035 Barcelona,
4 93 274 6083.
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1616 M. Miravitlles et al.Conclusions: Depression is frequent in COPD and is associated with suicidal ideation, impaired
HRQoL, increase in comorbidities, a reduction in physical activity and increased severity of
COPD measured by the BODEx index.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Comorbidities are frequent in patients with chronic
obstructive pulmonary disease (COPD) and have an impact
on the severity of the clinical manifestations and prognosis
[1,2]. Among the comorbidities, depression is one of the
most frequent, since even mild COPD patients have an in-
crease in the prevalence of depression of more than 4-fold
compared with controls [3]. Nonetheless, precise data on
depression rates in patients with COPD are lacking, with
estimates ranging from 6 to 71% [4,5]. Patients with COPD
and comorbid depression have more exacerbations [6,7],
reduced health-related quality of life (HRQoL) [8,9],
increased health resource use [10] and increased mortality
[5,11,12]. Moreover, COPD is a risk factor for the develop-
ment of depression [5], particularly in patients with
increased disability [13]. The identification of depressive
symptoms in COPD is particularly important because these
patients are candidates for specialized care that can result
in improved outcomes [14]. Therefore, early identification
of depression in COPD is crucial and studies aimed at
identifying the characteristics associated with a higher
prevalence of depressive symptoms could assist clinicians in
this task.
In the current study, information was collected from a
large cohort of unselected subjects with COPD in both pri-
mary and secondary care with the aim of investigating the
prevalence of depressive symptoms and clinically signifi-
cant (moderate to severe) depression in COPD. The sec-
ondary objective was to identify the factors significantly
associated with depression and significant depression in
COPD. The original Beck’s Depression Inventory (Beck’s DI)-I
in its short version of 13 items was used in our study [15]. It
takes approximately 5 min to complete and has high in-
ternal consistency and good discriminant and convergent
validity [16], and has been used previously to investigate
the impact of depression on outcomes in COPD [6,12,17].
Method
Study design
TheDEPREPOC (Depression in Chronic Obstructive Pulmonary
Disease) is an observational, cross-sectional, multicenter
study designed to analyze the prevalence of depression in
COPD patients and to identify factors associated with
depression and significant depression in this population.
Participating investigators were respiratory specialists and
primary care physicians from centers located throughout
Spain. Each investigator was requested to include the first
unselected patient that fulfilled all the inclusion and exclu-
sion criteria over a period of three consecutive days.Study population
The inclusion criteria were ambulatory stable COPD, age 40
years or older, current or ex-smokers with a smoking history
of at least 10 pack-years. The diagnosis of COPD had to be
confirmed by a spirometric test performed in a stable state
showing post-bronchodilator FEV1/FVC < 70%. The exclu-
sion criteria were an exacerbation in the preceding 3
months and the inability to read and/or understand the
questionnaires used in the study.
The study was approved by the Research and Ethics
Committee of the Hospital Clı´nic (Barcelona, Spain). All
included patients provided written informed consent.Measurements
The investigator completed a case report form (CRF),
including sociodemographic and clinical variables. COPD
severity was evaluated using the BODEx (Body mass index,
airflow Obstruction, Dyspnea and Exacerbations) index [18]
and the comorbidities were assessed with the Charlson
comorbidity index [19]. The level of physical activity was
estimated by the self-declared mean time in minutes sub-
jects had walked every day in the previous week, as in
previous studies [20e22].
Health-related quality of life was assessed by the
generic EuroQoL-5 dimensions (EQ-5D) questionnaire and
the specific COPD Assessment Test (CAT). The EQ-5D is a
generic HRQoL questionnaire that consists of two parts.
The first is a description of health status in five di-
mensions: mobility, personal care, daily activities, pain/
discomfort and anxiety/depression. Scores are pooled in a
global index ranging from 0 (worst state of health
possible) to 1 (perfect state of health). In the second part,
the subject scores his/her state of health on a 10-cm vi-
sual analog scale (VAS) between 0 (worst possible) and 100
(best possible) which has been validated in Spanish [23].
The CAT is a short, specific quality of life questionnaire for
measuring the impact of COPD on the patient’s wellbeing
and daily life. It is based on 8 items that are scored be-
tween 0 and 5, with a total score that ranges from 0 to 40,
in which higher scores mean a higher impact of the dis-
ease on the patient [24]. The CAT has been translated and
validated in Spanish [25].
The patient’s cognitive status was evaluated by the Mini
Mental State Examination (MMSE) [26] that also identified
dementia and delirium. It consists of a series of questions
and tasks grouped under 11 categories: orientation to time,
orientation to place, registration, attention and calcula-
tion, recall, language, repetition, understanding, reading,
writing and drawing. Each item is scored 1 or 0 depending if
the answer is correct or not. The MMSE, which has been
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score for all the items [27].
Depressive symptoms were measured using the Beck
Depression Inventory (Beck’s DI)-I questionnaire. The
Beck’s DI is a self-reported 21-item measure that ranges
from 0 to 63 and a score of 10 or higher is consistent with
mild to moderate depressive symptoms [15]. In this study,
the short 13-item version was used for evaluation of the
severity of depressive symptoms. The scores range from
0 to 39 and the established cut off points are the following:
0e4 Z no depression, 5 to 7 Z mild depression, 8 to
15 Z moderate depression and higher than 15 Z severe
depression [16]. Additionally, one question about suicidal
ideation and suicidal attempts was included.
Statistical analysis
The results of the continuous variables are presented with
the mean  standard deviation (SD), while categorical
values are described with frequencies and percentage.
Fisher’s exact test was used for comparisons of qualitative
variables. Student’s T-test (for two independent samples)
or the ANOVA test (for more than two samples) were used
to determine the relationship between qualitative variables
by group. The Pearson’s correlation coefficient was calcu-
lated to determine the relationship between 2 quantitative
variables.
Odds ratio (OR) univariates were calculated by logistic
regression to evaluate the different risks contemplated in
the study. After stepwise analysis, the various adjusted OR
were calculated using multivariate logistic regression. The
first model was developed with depression as a dependent
variable and all variables that showed a significant associ-
ation with depression in univariate analysis as independent
variables (model 1). A second model (model 2) excluded
any variables derived from the use of the questionnaires
from the independent variables. The objective of model 2
was to identify the factors associated with depression that
can be identified in routine clinical practice without the
administration of questionnaires. The same multivariate
analysis was performed with “severe depression” as the
dependent variable (model 3 with all the significant inde-
pendent variables and model 4 excluding the
questionnaires).
Statistical significance was considered if p was 0.05. All
statistical analyses were performed using SAS version 9.1.3
Service Pack 3 software.
Results
Population characteristics
A total of 1273 patients were recruited, of which 406 were
excluded as they did not meet the inclusion criteria (6 were
younger than 40 years, 48 were never smokers or smoked
less than 10 pack-years, 146 did not provide spirometry, 148
did not have airflow obstruction, 24 had cognitive impair-
ment and 34 did not complete the Beck’s DI and could not
be analyzed for the study objective). The remaining 836
(68.1%) patients were evaluable for analysis.The characteristics of the population are described in
Table 1. Most were men (83%) and the mean age was 68.3
years (SD Z 9.3), 22.9% were active smokers and mean
tobacco consumption was 41.9 pack-years. Most patients
were symptomatic with 96.4% experiencing dyspnea on
exertion and a mean post-bronchodilator FEV1 (%) of 52.1%
(SDZ 17.2%). The mean BODEx score was 2.94 (SDZ 1.86).
Quality of life, mood, activity and cognitive status
The mean value of the EQ-5D index was 0.62 (SD Z 0.24)
and the VAS 57.2 (SDZ 18.6). Regarding the CAT, the mean
value was 21.5 (SD Z 8). Patients claimed to walk a mean
of 64.7 (SD Z 52.2) minutes per day during the previous
week. The mean MMSE score was 26.2 (SDZ 4.2) (Table 2).
Prevalence and severity of depression and
correlations of Beck’s DI scores
The mean Beck’s DI was 8.9 (SDZ 6); a total of 647 (74.6%)
had a score of 5 or more, consistent with some degree of
depressive symptoms, with 119 (14.2%) having a score
higher than 15, consistent with severe depression, and 312
(37.3%) had moderate and 216 (25.8%) had mild depression.
Correlations of the Beck’s DI with clinical, spirometric
and questionnaire variables are depicted in Table 3 and
Fig. 1. There was a significant correlation between the
Beck’s DI scores and years since onset of COPD (r Z 0.14;
p < 0.0001), the number of ambulatory and hospital-based
exacerbations (r Z 0.22 and r Z 0.23 respectively, both
p < 0.0001) and the BODEx severity score (r Z 0.38;
p < 0.0001). There was also a significant correlation be-
tween the BECK’S DI and the MEC, the Charlson index and
the minutes walked per day. However, the strongest cor-
relations were found between the Beck’s DI and the quality
of life scores: r Z 0.59 (p < 0.0001) for the EQ-5D VAS,
r Z 0.62 (p < 0.0001) for CAT and r Z 0.72 (p < 0.0001)
for EQ-5D index (Table 3). Interestingly the correlation of
Beck’s DI and FEV1 (%) was not significant (Fig. 1).
Factors associated with the presence of depression
In the univariate analysis, depression was associated with
living alone, more frequent respiratory symptoms and exac-
erbations and more comorbidities (higher Charlson index). A
more severe COPD measured by the BODEx index, and more
impaired health status (EQ-5D and CAT) were also associated
with depression. In addition, lower levels of physical activity,
more cognitive impairment and suicidal thoughts were more
frequent in depressed patients (Table 4).
On multivariate analysis only the impairment in health
status (EQ-5D and CAT) and in cognitive function (MMES)
were independently and significantly associated with the
presence of depression (Table 4).
When the questionnaires were excluded from the model
and the analysis was limited to the usual demographic and
clinical variables, the significant factors in the multivariate
analysis were the history of exacerbations, a worse BODEx
index, an increased Charlson comorbidity index and a
reduction in minutes walked per day (Table 5).
Table 1 Characteristics of patients with and without depression according to BDI scores.
Variable Total Depression No depression P
Sex, males, (n, %) 713 (83%) 527 (82.1%) 186 (85.7%) 0.25
Age, year (mean, SD) 68.3 (9.3) 68.3 (9.1) 68.3 (9.8) 0.96
Life situation, (n, %)
Alone 115 (13.4%) 94 (14.6%) 21 (9.6%) 0.006
With partner 595 (69%) 425 (66%) 170 (78%)
With family 136 (15.8%) 109 (16.9%) 27 (12.4%)
Level of studies, (n, %)
Primary level not completed 74 (8.6%) 55 (8.6%) 19 (8.7%) 0.033
Primary level 501 (58.2%) 387 (60.3%) 114 (52.1%)
Secondary level 180 (20.9%) 133 (20.7%) 47 (21.5%)
Completed university 106 (12.3%) 67 (10.4%) 39 (17.8%)
Active smoker, (n, %) 196 (22.9%) 148 (23.3%) 48 (21.8%) 0.70
Pack-years (mean, SD) 41.9 (21.1) 42.3 (20.4) 40.9 (22.9) 0.38
BMI (mean, SD) 27.6 (4.6) 27.7 (4.7) 27.5 (4.4) 0.59
Post-bronchodilator spirometry (mean, SD)
FVC, ml 2910 (920) 2898 (940) 2946 (860) 0.50
FVC,% 69.3 (18.4) 68.8 (18.9) 70.5 (17.0) 0.55
FEV1, mL 1681 (734) 1673 (755) 1706 (668) 0.28
FEV1,% 52.1 (17.3) 51.6 (17.5) 53.6 (16.5) 0.15
FEV1/FVC 54 (12.5) 53.9 (12.7) 54.4 (11.9) 0.57
Cough, (n, %) 708 (82.8%) 554 (87%) 154 (70.6%) <0.0001
Expectoration, (n, %) 614 (73%) 481 (77%) 133 (61.3%) <0.0001
Dyspnea grade (mean, SD) 1.88 (0.9) 2.07 (0.8) 1.32 (0.7) <0.0001
Patient with exacerbations (n, %) 744 (85.8%) 592 (91.5%) 152 (69.1%) <0.0001
Ambulatory exacerbations (mean, SD) 2.6 (2) 2.7 (2) 2.1 (1.7) 0.001
Hospital exacerbations (mean, SD) 1.4 (2.1) 1.5 (2.2) 0.9 (1.6) 0.007
Charlson Index (mean, SD) 1.4 (1.4) 1.6 (1.5) 0.9 (1.1) <0.0001
LTOT, (n, %) 199 (23.9%) 179 (28.8%) 20 (9.5%) <0.0001
MMSE (mean, SD) 26.2 (4.2) 25.5 (4.5) 28.4 (2.2) <0.0001
Suicide attempt, (n, %) 21 (2.6%) 19 (3.1%) 2 (0.9%) 0.12
Time walked per day (min) 64.7 (52.2) 56.9 (48.8) 85.7 (55.3) <0.0001
EQ-5D (mean, SD) 0.62 (0.24) 0.55 (0.21) 0.83 (0.16) <0.0001
VAS (mean, SD) 57.2 (18.6) 52.7 (17.8) 70.3 (14.2) <0.0001
CAT (mean, SD) 21.5 (8) 23.9 (6.8) 14.5 (7.0) <0.0001
BECK (mean, SD) 8.9 (6.1) 11.1 (5.5) 2.5 (1.3) <0.0001
BODEx (mean, SD) 2.9 (1.9) 3.2 (1.8) 2 (1.6) <0.0001
BMI: Body mass index; LTOT: Long-term oxygen therapy; MMSE: Mini Mental State Examination; EQ-5D: EuroQoL-5 dimensions ques-
tionnaire; VAS: Visual analog scale; CAT: COPD Assessment Test; BDI: Beck depression inventory.
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depression
In the multivariate analysis only health status (EQ-5D and
CAT) and suicidal ideation were significantly associated
with severe depression (Table 6).
When the questionnaires were excluded, a worse BODEx
index, more comorbidity and less minutes per day walking
weresignificantlyassociatedwithseveredepression (Table7).
Discussion
Depression is a frequent comorbidity in COPD. Our results
show that almost three quarters of a large population of
unselected COPD patients have some degree of depressive
symptoms and up to 51.5% have a Beck’s DI score consistent
with moderate or severe depression. The presence ofdepression was associated with the history of exacerbations
and a worse HRQoL, both in the generic (EQ-5D) and specific
(CAT score) indexes. In the case of moderate to severe
depression, suicidal ideation was also significant in the
model. When the analysis was restricted to clinical vari-
ables, depression was again associated with exacerbations,
together with more comorbidities, reduced physical activ-
ity and a worse BODEx index. The results for severe
depression were similar but a history of exacerbations was
not significant in the model, probably because a history of
exacerbations is already included in the BODEx index.
The prevalence of clinically significant depressive
symptoms (moderate or severe) in our population was high
in comparison with other studies in COPD populations.
Prevalence estimates vary widely due in part to the use of
varied measurement tools and to the different degrees of
illness severity. In the review by Maurer et al. [4], the
prevalence of clinical depression in COPD ranged between
Table 2 Characteristics of patients with different degrees of severity of depression according to BDI scores.
Variable No depression Mild Moderate Severe P
Sex, males, (n, %) 186 (85.7%) 183 (86.0%) 256 (82.3%) 88 (74.6%) 0.045
Age, years (mean, SD) 68.4 (9.8) 67.3 (8.5) 68.7 (9.3) 69.3 (9.8) 0.25
Life situation, (n, %)
Alone 21 (9.6%) 24 (11.2%) 51 (16.4%) 19 (16.1%) <0.0001
With partner 170 (78%) 166 (77.2%) 195 (62.7%) 64 (54.2%)
With family 27 (12.4%) 25 (11.6%) 56 (18.0%) 28 (23.7%)
Level of studies, (n, %)
Illiterate 19 (8.7%) 14 (6.6%) 32 (10.3%) 9 (7.6%) 0.06
Primary level 114 (52%) 123 (58%) 189 (60.8%) 75 (63%)
Secondary level 47 (21.5%) 44 (20.7%) 63 (20.3%) 26 (21.8%)
University level 39 (17.8%) 31 (14.6%) 27 (8.7%) 9 (7.6%)
Active smoker, (n, %) 172 (78.2%) 173 (82%) 232 (75.3%) 82 (70.7%) 0.09
Pack-years (mean, SD) 40.9 (22.9) 41.6 (20.3) 41.9 (20.3) 45 (20.7) 0.41
BMI (mean, SD) 27.5 (4.4) 28 (4.6) 27.7 (4.5) 27.1 (5.3) 0.38
Postbronchodilator spirometry (mean, SD)
FVC, ml 2946 (860) 2885 (914) 2946 (943) 2793 (976) 0.40
FVC,% 70.5 (17) 68 (20.4) 70.7 (17.3) 65 (18.9) 0.37
FEV1, mL 1706 (668) 1627 (711) 1722 (764) 1625 (805) 0.052
FEV1,% 53.6 (16.5) 50 (17.4) 53.8 (16.6) 48.9 (19.6) 0.01
FEV1/FVC 54.4 (11.9) 54.1 (12.6) 53.9 (12.4) 53.4 (13.5) 0.91
Cough, (n, %) 154 (70.6%) 171 (80.3%) 276 (89.6%) 107 (92.2%) <0.0001
Expectoration, (n, %) 133 (61.3%) 148 (70.5%) 234 (78.3%) 99 (85.3%) <0.0001
Dyspnea grade (mean, SD) 1.3 (0.7) 1.8 (0.8) 2 (0.8) 2.6 (0.9) <0.0001
Patient with exacerbations (n, %) 162 (62.1%) 196 (90.7%) 283 (90.7%) 113 (95.0%) <0.0001
Ambulatory exacerbations (mean, SD) 2.1 (1.7) 2.4 (1.8) 2.7 (1.8) 3.4 (2.8) <0.0001
Hospital exacerbations (mean, SD) 0.9 (1.6) 1.1 (2.4) 1.4 (1.5) 2.4 (3) <0.0001
Charlson Index (mean, SD) 0.9 (1.1) 1.1 (1.1) 1.6 (1.4) 2.3 (2.0) <0.0001
LTOT, (n, %) 20 (9.5%) 30 (14.7%) 83 (27.4%) 66 (57.4%) <0.0001
MMSE (mean, SD) 28.4 (2.2) 26.9 (3.3) 25.5 (4.0) 23 (5.9) <0.0001
Suicide attempt, (n, %) 2 (0.9%) 3 (1.4%) 7 (2.3%) 9 (8.0%) 0.002
Time walked per day (min) 85.7 (55.3) 66.1 (59) 55.9 (42.6) 37.8 (33) <0.001
EQ-5D (mean, SD) 0.83 (0.16) 0.69 (0.14) 0.54 (0.18) 0.33 (0.21) <0.0001
VAS (mean, SD) 70.3 (14.2) 61.8 (14) 51.3 (16.3) 39.2 (18.3) <0.0001
CAT (mean, SD) 14.5 (7) 20.4 (6.4) 24.4 (6.2) 29.1 (5.1) <0.0001
BDI (mean, SD) 2.5 (1.3) 6.1 (0.8) 11 (2.3) 20.3 (4.2) <0.0001
BODEx index (mean, SD) 2.0 (1.7) 3 (1.7) 3 (1.8) 4.4 (1.9) <0.0001
BMI: Body mass index; LTOT: Long-term oxygen therapy; MMSE: Mini Mental State Examination; EQ-5D: EuroQoL-5 dimensions ques-
tionnaire; VAS: Visual analog scale; CAT: COPD Assessment Test; BDI: Beck depression inventory.
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oxygen-dependent patients. However, in the studies that
focused on patients with severe disease, the prevalence of
depression ranged from 37% to 71%, figures comparable to
or higher than prevalence rates in other advanced diseases
such as cancer, AIDS, heart disease, and renal disease [4].
Studies using the Beck’s DI have observed prevalences of
depression of between 19.8% [12] to 40.8% in severe COPD
[17] or 39% in hospitalized patients without a previous
diagnosis of depression [6]. One of the largest studies to
date used the Center for Epidemiologic Studies of Depres-
sion (CES-D) questionnaire in a population of 2118 COPD
patients and found a prevalence of depression of 26%
compared with 12% of smokers and 7% of nonsmokers [8]. In
relation to the general population, there is one Spanish
study in subjects between 18 and 64 years that reported
4.16% of individuals with a Beck’s DI score of 13 units or
higher [28]; unfortunately, no reference data in the elderly
are available.It is crucial to identify depressive symptoms in patients
with COPD because they are associated with worse out-
comes and even with an increase in mortality
[5,6,11,12,17]. Furthermore, specific treatment may result
in improved survival. A study in a population of 5527 vet-
erans with COPD in the US reported that patients seen in
mental health settings during their depressive episode had
30% lower odds of 2-year mortality than patients seen in
primary care, highlighting the importance of identifying
significant depressive symptoms in COPD and providing
specialized care [18].
For the early detection of depressive symptoms in COPD,
patients at more risk must be identified by recognizing the
factors that are significantly associated with a higher
prevalence of moderate or severe depression. Beck’s DI
scores were found to correlate better with the quality of
life questionnaires (r Z 0.728 with the EQ-5D and
r Z 0.626 with the CAT; p < 0.0001 for both correlations)
and with cognitive function (r Z 0.439 with the MMSE;
Table 3 Correlations of BDI scores with different contin-
uous variables.
Variable Correlation
with Beck
P
Age 0.0328 0.33
Pack-years 0.0546 0.11
BMI 0.0178 0.60
Time since onset of COPD (years) 0.1401 <0.0001
Post-Bronchodilator FEV1 (ML) 0.0052 0.87
Number of COPD exacerbations
treated in outpatients
0.2224 <0.0001
Hospital exacerbations 0.2331 <0.0001
Charlson index score 0.3512 <0.0001
Total MMSE 0.4396 <0.0001
Minutes walked 0.3049 <0.0001
EQ-5D (utility) 0.7286 <0.0001
CAT score 0.6263 <0.0001
BODEx index 0.3839 <0.0001
BMI: Body mass index; MMSE: Mini Mental State Examination;
EQ-5D: EuroQoL-5 dimensions questionnaire; CAT: COPD
Assessment Test.
a)
b)
c)
d)
Figure 1 Correlations between Beck’s DI scores and a)
Postbronchodilator FEV1 (% predicted); b) CAT scores; c) mi-
nutes walked per day; d) EQ-5D utilities.
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tion between depressive symptoms in COPD and poor
HRQoL and cognition. In the multivariate analysis, both
quality of life questionnaires and cognitive function were
the variables significantly and independently associated
with the presence of depressive symptoms, but in the
model for severe depression, MMSE scores were replaced by
suicidal ideation. The use of HRQoL questionnaires or the
MMSE is not routine clinical practice in most primary care
offices; therefore, we performed a multivariate model
discarding the scores of these questionnaires and including
only demographic and clinical variables. In these models,
the presence of depressive symptoms was associated with
the history of exacerbations, the severity of COPD
measured by the BODEx index, increased comorbidities and
a reduced level of physical activity measured by minutes
walked per day. In the model for moderate to severe
depression, only the severity of COPD measured by the
BODEx index, increased comorbidities and decreased
physical activity were significant. Similarly, Al-shair et al.
[29] found a significant association between depression and
COPD severity when BODE scores were used but not with
GOLD stages based on FEV1 (%) thresholds. Another study
found that the BODE index was superior to FEV1 (%) for
explaining symptoms of anxiety and depression [30].
Exacerbations are frequent events in the natural history
of COPD. They are associated with increased health care
costs [31] and significant impairment in HRQoL of patients
[32], and in our study showed a strong association with the
presence of depressive symptoms. Moreover, a large follow-
up study has found an increased risk of exacerbations
(adjusted incidence rate ratio (IRR), 1.51; 95% confidence
interval (CI), 1.01e2.24) and hospitalizations (adjusted IRR,
1.72; 95%CI, 1.04e2.85) in patients with probable depres-
sion identified by HADs (Hospital Anxiety and Depression)
scores 11, compared with patients without depression [7].
One of the key manifestations of depressive symptoms is
the reduction in physical activity. Due to the cross-sectionaldesign of the study, we could not use objective measure-
ments of physical activity such as accelerometers, but we
found a good correlation between the self-declared mean
time walked per day and the scores of the Beck’s DI.
Table 4 Factors associated with depression in univariate and multivariate analysis.
Variable Univariate Multivariate
OR CI95% P value OR CI95% P value
Lives with partner vs alone 0.56 0.34e0.93 <0.05
Cough 2.77 1.91e4.02 <0.05
Expectoration 2.11 1.52e2.94 <0.05
Dyspnea 6.7 3.1e14.46 <0.05
Exacerbations (yes vs no) 4.82 3.24e7.17 <0.05
MMSE score 0.73 0.67e0.79 <0.05 0.84 0.76e0.92 <0.05
Suicidal thinking 5.17 2.36e11.33 <0.05
EQ-5D 0.92 0.91e0.93 <0.05 0.939 0.92e0.95 <0.05
CAT Score 1.21 1.17e1.25 <0.05 1.123 1.08e1.16 <0.05
Charlson index 1.55 1.34e1.79 <0.05
BODEx score 1.48 1.33e1.65 <0.05
MMSE: Mini Mental State Examination; EQ-5D: EuroQoL-5 dimensions questionnaire; CAT: COPD Assessment Test.
Multivariate analysis included the following variables: sex, living with partner (yes/no), level of studies, cough (yes/no), expectoration
(yes/no), dyspnea degree, exacerbations previous year (yes/no), long-term oxygen therapy (yes/no), Charlson index, MMSE score, post-
bronchodilator FEV1(%), minutes walked per day, CAT score and BODEX.
Depression in COPD 1621Moreover, time walked per day was one of the variables
that remained significant in all multivariate models indi-
cating a strong association with depressive symptoms. In
fact, minutes walked per day has been used as a reliable
marker of physical activity in other studies in populations
with COPD [20e22], and its association with depression has
been demonstrated using the HAD scale [22]. Accordingly,
minutes walked per day has been incorporated as a marker
of severity in recent guidelines [33]. The reduction in ac-
tivity associated with depression in COPD has been
observed in previous studies using the activity domain of
the St. George’s Respiratory Questionnaire [11] and simi-
larly, a significant increase in fatigue has also been
described in depressed individuals with COPD [8]. Other
studies have also demonstrated a strong relationship be-
tween depression in COPD and a significantly reduced ex-
ercise capacity measured by the six-minute walking test
[29,30].
The relationship between depression and impaired
HRQoL in patients with COPD has been extensively reportedTable 5 Factors associated with depression in univariate and m
characteristics.
Variable Univariate
OR CI95%
Live with partner vs alone 0.56 0.34e0.93
Cough 2.77 1.91e4.02
Expectoration 2.11 1.52e2.94
Exacerbations (yes vs no) 2.86 1.88e4.34
Long term oxygen therapy 3.96 2.77e5.67
History of COPD (years) 1.05 1.02e1.07
Charlson index 1.55 1.34e1.79
Minutes walked per day 0.99 0.98e0.99
BODEx index 1.48 1.33e1.65
Multivariate analysis included the following variables: sex, living with
(yes/no), dyspnea degree, exacerbations previous year (yes/no)
bronchodilator FEV1(%), minutes walked per day and BODEX.[8,9,11,34,35]. In a population of 326 patients with COPD,
depression was the only comorbidity associated with a
significant impairment in HRQoL [35]. Our results show a
strong correlation between the Beck’s DI and the CAT
scores, a new short health status questionnaire appropriate
for use in routine clinical practice in COPD [24,36]. Simi-
larly, a recent study observed that depression, together
with anxiety and changes in dyspnea scores were the only
factors significantly associated with changes in the CAT
score over time [37]. Finally, since depression in COPD is
associated with more severe BODE or BODEx scores, an
increased frequency of exacerbations and hospitalizations,
and impaired HRQoL, higher health care resource utiliza-
tion is observed in COPD patients with depressive symptoms
should not be surprising [10]. One limitation of our study is
that most of our patients were men, according to the
epidemiology of COPD in Spain [38], and therefore the re-
sults may not be extrapolated to women with COPD.
In summary, depressive symptoms are frequent in COPD,
even more than in other chronic conditions [4,39], andultivariate analysis, including only demographic and clinical
Multivariate
P value OR CI95% P value
<0.05
<0.05
<0.05
<0.05 2.76 1.59e4.81 <0.05
<0.05
<0.05
<0.05 1.52 1.23e1.88 <0.05
<0.05 0.99 0.98e0.99 <0.05
<0.05 1.65 1.33e2.05 <0.05
partner (yes/no), level of studies, cough (yes/no), expectoration
, long-term oxygen therapy (yes/no), Charlson index, post-
Table 6 Factors associated with severe depression in univariate and multivariate analysis.
Category Univariate Multivariate
OR CI95% P value OR CI95% P value
Men vs women 0.49 0.28e0.86 <0.05
Lives with partner vs alone 0.42 0.21e0.82 <0.05
BMI (25e29.9 vs 18.5e24.9) 0.55 0.32e0.93 <0.05
Cough 4.94 2.36e10.36 <0.05
Expectoration 3.68 2.05e6.59 <0.05
Dyspnea score 5.72 3.91e8.36 <0.05
Exacerbations (yes vs no) 8.43 3.53e20.1 <0.05
Long term oxygen therapy 12.65 6.99e22.88 <0.05
MMSE score 0.68 0.61e0.75 <0.05
Suicidal ideation 18.34 7.91e42.51 <0.05 6.213 1.36e28.24 <0.05
Any suicide attempt 9.39 1.99e44.23 <0.05
EQ-5D 0.86 0.83e0.89 <0.05 0.899 0.86e0.93 <0.05
CAT Score 1.42 1.32e1.53 <0.05 1.325 1.19e1.46 <0.05
Charlson index 1.79 1.50e2.13 <0.05
BODEx score 1.98 1.66e2.37 <0.05
BMI: Body mass index; MMSE: Mini Mental State Examination; EQ-5D: EuroQoL-5 dimensions questionnaire; CAT: COPD Assessment Test.
Multivariate analysis included the following variables: sex, living with partner (yes/no), level of studies, cough (yes/no), expectoration
(yes/no), dyspnea degree, exacerbations previous year (yes/no), long-term oxygen therapy (yes/no), Charlson index, MMSE score, post-
bronchodilator FEV1(%), minutes walked per day, CAT score and BODEX.
1622 M. Miravitlles et al.according to some series, patients with COPD are at
increased risk of developing depression [5,40] particularly if
their level of disability increases [13]. Early detection of
depressive symptoms is crucial because these symptoms are
associated with worse outcomes, including increased mor-
tality, and can be potentially treated. Patients with
frequent exacerbations, reduced levels of physical activity
and worse CAT and BODE/BODEx scores should be screened
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